EAGLE PHARMACEUTICALS INC. - COMMON STOCK

Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

09 Nov 2022 06:50:01 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reports Third Quarter 2022 Results

07 Nov 2022 06:50:01 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

31 Oct 2022 06:50:00 By Nasdaq GlobeNewswire

SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

19 Oct 2022 16:39:54 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia

12 Oct 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant

03 Oct 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001

27 Sep 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

30 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

18 Aug 2022 12:53:23 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reports Second Quarter 2022 Results

09 Aug 2022 06:50:01 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

09 Aug 2022 06:45:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022

28 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

18 Jul 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

09 Jun 2022 07:30:01 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

01 Jun 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference

26 May 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reports First Quarter 2022 Results

09 May 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022

28 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

19 Apr 2022 06:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc

28 Mar 2022 04:00:00 By Nasdaq GlobeNewswire